.png){kind=logo}
GSP Crop Science was launched in the stock markets at a small premium on March 24, 2026, indicating the reserved investor feelings despite the good fundamentals. The agrochemical company traded at a gain of 2.5% on NSE, Rs. 328 as compared to the issue price of Rs. 320. On the BSE, the stock was trading stronger at the opening, at Rs. 332.30, which represents a 3.84% premium.
The IPO that was priced between Rs. 304-320 per share provided low listing-day returns. Investors who had been allocated shares recorded a gain of Rs. 8 per share in both the NSE and Rs. 12.30 per share in the BSE.
In a single lot of 46 shares, this will amount to a profit between Rs. 368 and Rs. 566, based on the price at which the shares are listed in the exchange market.
Even after the low IPO, the firm registered a market capitalization of approximately Rs. 1,545 crore in the post-listing period, which shows the investor confidence remains intact.
The IPO was a fresh issue of Rs. 240 Crore and an offer of sales (OFS) of Rs. 160 Crore by promoters. The magazine was subscribed to 1.61 times on average, indicating a moderate demand.
There was also a high level of institutional participation as the Qualified Institutional Buyers (QIBs) subscribed 2.66 times and Non-Institutional Investors (NIIS) bID 3.05 times their quota.
However, the retail involvement was restrained, with only 40% subscription, which indicates a reserved attitude by small investors.
Before the IPO, the company had collected Rs. 120 crore from anchor investors, such as Craft Emerging Market Fund and Shine Star Build Cap, which strengthens institutional support.
GSP Crop Science showed steady financial growth. In the 25th year, the company registered a profit after taxes of Rs. 83.44 crore, up 36% from Rs. 61.33 crore last year. The revenue increased by 11.7% year-on-year to Rs. 1,287.38 crore.
The company is involved in the agrochemical business, which involves the production of fungicides, herbicides, insecticides, and plant growth regulators. It has more than 524 registered products and 102 patents granted, which gives it a solid portfolio of innovation.
Also Read: SBI Mutual Fund IPO Pushed to September Amid US-Iran War
The fresh issue will be utilised as follows: about Rs. 170 crore will be utilised to settle debt, and the rest will be utilised in the general corporate purpose.
The company had total borrowings of Rs. 478.8 crore as of December 2025, which shows that the company was concentrated on the enhancement of its balance sheet.
